•  
  •  
  •  
  •  

2026-02-19 18:50:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Steelco Gujarat Launches ₹14.9 Cr Rights Issue
  • INOXGFL Group Companies Emerge as Successful Bidders For Wind World India's IPP and O&M Arms
  • Embraer and Mahindra Group Advance Localization Strategy in India with Planned C-390 Millennium MRO Capability
  • Hemant Surgical Bags ₹264 Cr Medical Equipment Order from Govt
  • LTM Partners with Indian Institute of Creative Technologies to build India's NextGeneration Creative Technology Talent Pipeline

Keywords Selected:  API

Stock Report

  • IOL Chemicals and Pharmaceuticals Ltd receives EDQM Ceritificate of Suitability for Sitagliptin Phosphate Monohydrate
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • USFDA successfully completes inspection at Indoco's API manufacturing facility at Patalganga with zero observations
  • Sigachi Industries Secures ToR approval for its Upcoming API and Specialty Chemicals Manufacturing Facility in Orvakal, Andhra Pradesh State
  • Lasa Supergenerics Ltd expands Manufacturing Capacity of API Albendazole to meet Global Demand
  • Wanbury Limited launching two new products, Formulation - Branded Hematinic Iron tablets, WANBURY C-RED and API- KETAMINE HYDROCHLORIDE
  • Closure of USFDA inspection at Zydus' API Unit 1 at Ankleshwar, Gujarat
  • J B Chemicals & Pharmaceuticals Ltd successfully completes USFDA inspection at API facility
  • EDQM issues CEP Certificate for IOL Chemicals and Pharmaceuticals Ltd's API Quetiapine Fumarate
  • Orchid Pharma's Alathur API facility successfully completes USFDA inspection
  • Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Teriflunomide
  • Shilpa Pharma Lifesciences Limited, received CEP from EDQM for API, Nifedipine
  • Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Octreotide
  • Shilpa Pharma Lifesciences Limited, received CEP from EDQM for API, Desmopressin
  • Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
  • Anuh Pharma Ltd received EDQM approval for CEP of Allopurinol API
  • Wanbury Ltd received CEP approval from EDQM for the launch of its new product, Dextromethorphan API
  • Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API
  • Shilpa Pharma Lifesciences Ltd received CEP from EDQM for API, Ursodeoxycholic Acid
  • Shilpa Pharma Lifesciences Ltd's Unit 2, Raichur, Karnataka has cleared the COFEPRIS-Mexico GMP Inspection
  • Shilpa Pharma Lifesciences Ltd, Unit 2, Raichur, Karnataka has cleared the ANVISA-Brazil GMP inspection
  • Chemiesynth Vapi Ltd Q4FY24 loss at Rs. 20.12 lakhs
  • Man Industries India Ltd's new ERW plant certified by API to manufacture ERW pipes
  • Imagicaa bags Two IAAPI National Excellence Awards 2023-2024 for Innovative Ride & Unique IP Event

Latest Post

  • Steelco Gujarat Launches ₹14.9 Cr Rights Issue
  • INOXGFL Group Companies Emerge as Successful Bidders For Wind World India's IPP and O&M Arms
  • Embraer and Mahindra Group Advance Localization Strategy in India with Planned C-390 Millennium MRO Capability
  • Hemant Surgical Bags ₹264 Cr Medical Equipment Order from Govt
  • LTM Partners with Indian Institute of Creative Technologies to build India's NextGeneration Creative Technology Talent Pipeline


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025